Castle Biosciences Inc
NASDAQ:CSTL

Watchlist Manager
Castle Biosciences Inc Logo
Castle Biosciences Inc
NASDAQ:CSTL
Watchlist
Price: 20.01 USD -1.43% Market Closed
Market Cap: 577.7m USD

Wall Street
Price Targets

CSTL Price Targets Summary
Castle Biosciences Inc

Wall Street analysts forecast CSTL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CSTL is 36.61 USD with a low forecast of 30.3 USD and a high forecast of 43.05 USD.

Lowest
Price Target
30.3 USD
51% Upside
Average
Price Target
36.61 USD
83% Upside
Highest
Price Target
43.05 USD
115% Upside
Castle Biosciences Inc Competitors:
Price Targets
HIMS
Hims & Hers Health Inc
3% Upside
PINC
Premier Inc
3% Upside
V3V
Vita 34 AG
59% Upside
RDNT
RadNet Inc
30% Upside
1951
Jinxin Fertility Group Ltd
27% Upside
9860
Adicon Holdings Ltd
39% Upside
THYROCARE
Thyrocare Technologies Ltd
4% Downside
LALPATHLAB
Dr. Lal PathLabs Ltd
11% Upside

Revenue
Forecast

Revenue Estimate
Castle Biosciences Inc

For the last 6 years the compound annual growth rate for Castle Biosciences Inc's revenue is 56%. The projected CAGR for the next 3 years is 0%.

56%
Past Growth
0%
Estimated Growth
Estimates Accuracy
0%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Castle Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
14%
Average Beat

Net Income
Forecast

Net Income Estimate
Castle Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-14%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CSTL's stock price target?
Price Target
36.61 USD

According to Wall Street analysts, the average 1-year price target for CSTL is 36.61 USD with a low forecast of 30.3 USD and a high forecast of 43.05 USD.

What is Castle Biosciences Inc's Revenue forecast?
Projected CAGR
0%

For the last 6 years the compound annual growth rate for Castle Biosciences Inc's revenue is 56%. The projected CAGR for the next 3 years is 0%.

Back to Top